Vitux Group as

Ntnu Technology Transfer as

Fmc Biopolymer as

Norskhydro Asa

Norwegian University of Science and Technology

Ayanda Group as

Ntnu Technology Transfers as

Kurt Ingar Draget

Ingvild Johanne Haug

Catherine Taylor

Tore Seternes

Olav Asmund Smidsrod

Olav Smidsr&oslash;d

Merethe Kamfjord Simensen

Freddy Johnsen

Finn Hjelland

&Oslash;istein B&aelig;kken

Therese Fj&aelig;reide

Edvar Ons&oslash;yen

Steinar Johan Engelsen

Magnus Hattrem

Olav Smidsro Slashedd

Magnus N Hattrem

Olav ÅSmund SMIDSRØD

Catherine Taylor Nordgård

The invention relates to an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.

Emulsion

The invention provides an oral pharmaceutical composition, optionally in dose unit form, comprising a lipophilic drug substance in dispersion in a physiologically tolerable aqueous carrier, preferably an aqueous gel, wherein said drug substance contains a functional electrostatic group having a pKa value of from 2 to 10, characterised in that said aqueous carrier has a pH at least 0.3 below or above said pKa value, said pH being below said pKa where said group is acidic and above said pKa where said group is basic.

Oral pharmaceutical dispersion compositions

An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.

Chewable gelled emulsions

A composition useful in gene therapy and a method of treatment to effect gene therapy is provided. In particular, a pharmaceutical composition comprising a nonimmunogenic net polyanionic oligosaccharide, such as an oligouronate, associated with a particulate complex of an anionic nucleic acid material and a cationic macromolecule, optionally together with at least one pharmaceutical carrier or excipient, is provided.

Composition for use in gene therapy

The invention provides a pharmaceutical composition comprising a macromolecular drug and an oligoguluronate or oligogalacturonate, e.g., having a number average degree of polymerization in the range 5 to 18, a guluronate (or galacturonate) fraction (F) of at least 0.80, a mannuronate fraction (F) of no more than 0.20, and having at least 95% mole with a degree of polymerization less than 20. The composition may be used in a method of treatment which comprises administering the composition to a mucosal surface in a human or non-human vertebrate subject.

Oligo-guluronate and galacturonate compositions

A method of treatment of a human or non-human subject to combat mucosal hyperviscosity in the respiratory tract, which method includes application to a mucosal surface in the tract in the subject of an effective amount of a physiologically tolerable oligouronate. Related compositions containing physiologically tolerable oligouronates are also described.

Use of oligouronates for treating mucus hyperviscosity

The invention provides a method of treatment of a female human or non-human subject to enhance cervical mucus penetrability by spermatozoa, which method comprises vaginally applying to said subject an effective amount of a spermicide-free, physiologically tolerable oligouronate.

Mucosal treatment

Provided are improvements in and relating to pharmaceutical compositions for oral administration of polymeric biological drug substances and to methods of treatment using such compositions. In particular, an oral and/or mucosal pharmaceutical composition is provided, said composition comprising an enteric-coated drug substance, and also comprising an enteric-coated oligouronate, wherein said drug substance is a polymeric biological drug substance.

Composition for the administration of polymeric drugs

The present invention relates to gelled feed products, means for making said products and a method for manufacturing gelled feed products. The product comprises 80-98 weight % raw material of animal or marine origin pre-treated with KOH and/or NaOH, KHCO , K CO , NaHCO , Na CO , or (NH ) CO and 0.5-5 weight % alginate or pectin, a calcium source standard feed ingredients and calcium. The product may contain 0-10 weight % fish meal or carbohydrates. Said means are raw material of animal or marine origin pre-treated with alkali giving said raw material a pH of 8-12. The method comprises mixing raw materials of marine or animal origin, comprising offals, alginate or pectin, and a calcium source and standard feed ingredients, particulating said mixture into any useful geometrical shape, expose it to acid treatment in a bath. The raw material is pre-treated with alkali or to addition of alginate or pectin. The resulting mixture is formed into desired shape and treated in an acid bath to form the gelled product. Preferably the acid bath is having a pH of 0.5-5.5 and the retention time in the bath is 30 seconds-12 hours. The preferred acid is formic aid.

Gelled feed products, means for making the products and method for manufacture of said products

The use of G-block polysaccharides as a modulator for the rheology in a mixture in which a gelling, water-soluble polysaccharide is a component to give the final product a changed viscosity, stability, elasticity, rigidity or similar.

Use of G-block polysaccharides

A new procedure for producing block fractions from alginate, mainly G block alginate or M block alginate, by selective fractionated release of the M block fraction from the solid phase. MG block fractions can also be isolated.

Growing community of inventors

Trondheim, Norway

Kurt Ingar Draget